Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find PharmaFlow Article for Phenobarbital

    Client Email Product

    Phenobarbital

    APIs // Active Pharmaceutical Ingredients

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    27
    US DMFs Filed

    US DMFs Filed

    10
    CEP/COS Certifications

    CEP/COS Certifications

    5
    JDMFs Filed

    JDMFs Filed

    10
    Other Certificates

    Other Certificates

    4
    Other Suppliers

    Other Suppliers

    6
    API REF. PRICE (USD / KG)
    54

    API Market Place

    20
    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    0

    Europe

    Europe

    19
    Canada

    Canada

    10
    Australia

    Australia

    2
    South Africa

    South Africa

    7
    Uploaded Dossiers

    Uploaded Dossiers

    13
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    189.00

    Annual Reports

    0

    FDF Market Place

    7
    EXCIPIENTS
    151
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    12
    REF STANDARD

    EDQM

    3

    USP

    1

    JP

    0

    Other Listed Suppliers

    4
    SERVICES

    0

    BlogBlog
    Full View ScreenFull Screen View
    With a $1.2 billion buy, Concordia re-affirms that old drugs are indeed gold!

    With a $1.2 billion buy, Concordia re-affirms that old drugs are indeed gold!

    Canada based, Concordia Healthcare continued their buying spree of old, established drug brands by announcing the acquisition of commercial assets of Covis Pharma S.a.r.l and Covis Injectables, S.a.r.l for US $1.2 billion in cash. The Covis deal comes right after Concordia’s $329 million purchase of Donnatal (belladonna alkaloids, phenobarbital) in May 2014. Concordia’s buy makes them add to their existing portfolio, 18 high-margin, branded and authorized generic pharmaceutical products from private-equity backed, Swiss-based, Covis. Authorized and branded generics of the following drugs are all part of the deal: Nilandron®, for the treatment of metastatic prostate cancer Dibenzyline®, for the treatment of pheochromocytoma (neuroendocrine tumor) Lanoxin®, for the treatment of mild-to-moderate heart failure and atrial fibrillation Plaquenil®, for the treatment of lupus and rheumatoid arthritis  Lanoxin, Dibenzyline and Plaquenil have been on the market in the United States for over 60 years  Covis 2014 revenues were between US$140 and $145 million with a 90% gross margin, while 38% of approximate Concordia’s US$ 120 million revenues came from Donnatal.  In their conference call, Concordia supported paying almost 8.5 times revenues with the following rationale: Lanoxin (Digoxin) – API and Finished Dosage manufacturing challenges have resulted in market supply shortages and the potential FDA implementation of NTI (Narrow Therapeutic Index) for Lanoxin can represent a future upside to this business. DiBenzyline (Phenoxybenzamine Hydrochloride) – is the preferred agent of choice with no generic competition. The opportunity exists to develop new orphan indications. Plaquenil (Hydrochloroquine) – API supplier to Ranbaxy, which held 90% market share, exited the market in 2014 due to a voluntary market withdrawal and currently competitors are not positioned well to meet the existing demand. Nilandron (Nilutamide) – absence of generic competition due to strict ANDA guidelines coupled with excellent payer coverage. Covis’ 2014 revenues contributions were:  Lanoxin 25%  Dibenzyline 17% Nilandron 16%  Plaquenil 15%  So while pharmaceutical companies are looking at next generation molecules to grow their revenue streams, a look back in time may provide some worthwhile opportunities. 

    Impressions: 4865

    subscribeSubscribe
    ExcelExcel Download

    https://www.pharmacompass.com/radio-compass-blog/with-a-1-2-billion-buy-concordia-re-affirms-that-old-drugs-are-indeed-gold

    #Phispers by PHARMACOMPASS
    10 Mar 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search